Ciprofloxacin after clinical failure of β-lactam antibiotics in children with salmonellosis;Ciprofloxacine après échec des β-lactamines dans les salmonelloses de l'enfant

Archives de Pediatrie

Volumn 10, Issue 7, 2003, Pages 608-614

  Moulin, F ^a   Sauve Martin H ^a   Marc, E ^a   Lorrot, Mathie M ^a   Soulier, M ^a   Ravilly, S ^a   Raymond, J ^a   Gendrel, D ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Anti infective agents, quinolone; Child; Salmonella infection; Thyphoid fever, therapy

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFTRIAXONE; CIPROFLOXACIN;

ADOLESCENT; ARTICLE; BACTERIOLOGY; BACTERIUM ISOLATION; CHILD; CONVALESCENCE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSENTERY; ENZYME SYNTHESIS; FEMALE; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; SALMONELLA; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SHOCK; SIDE EFFECT; STRAIN DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; TYPHOID FEVER;

EID: 0042233625     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00281-1     Document Type: Article

References (34)

1. Asperilla MO, Smego Jr RA, Scott LK. Quinolone antibiotics in the treatment of Salmonella infections. Rev Infect Dis 1990;12:873-89.
2. Miller SL, Hohmann EL, Pegues DA. Salmonella. 4th ed. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. New-York: Churchill-Livingstone; 1995. p. 2013-33.
3. Gendrel D. Salmonelloses de l'enfant. Encycl Méd Chir. Paris: Elsevier; 1997. p. 1-8 Maladies infectieuses 8-018-A-10.
4. Ashkenazi S, Cleary T. Antibiotic treatment of bacterial gastroenteritis. Pediatr Infect Dis J 1991;10:140-8.
5. Pickering LK, Cleary TG. Approach to patients with gastro-intestinal tract infections and food poisoning. 4th ed. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. Philadelphia: Saunders; 1998. p. 567-600.
6. Gendrel D, Raymond J, Le Gall MA, Bergeret M, Badoual J. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. Eur J Clin Microb Infect Dis 1993;12:209-11.
7. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a 3-months course of ciprofloxacin. Pediatr Infect Dis J 1991;10:723-9.
8. Aradottir E, Yogev R. The use of fluoroquinolones in pediatrics: a reassessment. Sem Pediatr Infect Dis 1999;10:31-7.
9. Gendrel D, Moulin F. Fluoroquinolones in Paediatrics. Paediatr Drugs 2001;3:365-77.
10. Leibovitz E, Janco J, Piglansky L, Press J, Yagupsky P, Reinhart H, et al. Oral ciprofloxacin vs intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2000;19:1060-7.
11. Kuhn R, Kanga J, Palmejar A, et al. Retrospective review of ciprofloxacin for the treatment of acute pulmonary exarcebation in the pediatric CF patient. Pediatr Pulmonol 1990;5:246S-52S.
12. Chysky V, Kapila K, Hullmann R, et al. Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991;19:289-96.
13. Schaad UB, Sander E, et al. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in 2 juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992;11:1047-9.
14. Schaad UB, Abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus. Report of an International Society of Chemotherapy Commission. Pediatr infect Dis J 1995;14:1-9.
15. Hampel MD B, Hullmann MS R, Schmidt AD H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997:127-9.
16. Jick S. Ciprofloxacin safety in pediatric population. Pediatr Infect Dis J 1997;16:130-4.
17. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr Infect Dis J 1997 Jun;16(6):572-8.
18. St Geme JW, Hodes HL, Marcy SM, et al. Consensus: management of Salmonella infection in the first year of life. Pediatr Inf Dis J 1988;7: 615-21.
19. Dutta P, Rasaily R, Saha MR, et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993; 37:1193-9.
20. Green SD, Ilunga FM, Numbi A, Cheesbrough JS, Tillotson GS. An open study of cirpofloxacin for the treatment of proven or suspected extra-intestinal salmonellosis in African children: a preliminary report. Adv Antimicrob Agents Chemother 1992;11:181-7.
21. Cheesbrough JS, Mwema FI, Green SD, Tillotson GS. Quinolones in children with invasive salmonellosis. Lancet 1991;338:127.
22. Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with non Salmonella typhi. Rev Infect Dis 1984;6:345-56.
23. Peltola H, Vaarala M, Renkonen V, et al. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36:1086-90.
24. Jacqz-Aigrain E, Brun P, Bennasr S, Loirat C. Side effects of pefloxacin in idiopathic nephrotic syndrome. Lancet 1993;342:438-9.
25. Aujard Y, Gendrel D. Les quinolones en pédiatrie, 1 vol. Paris: Flammarion Éd.; 1994.
26. Menschik M, Neumuller J, Steiner CW, et al. Effects of ciprofloxacin and floxacin on adult human cartilage in vitro. Antimicrob Agents Chemother 1997;41:2562-5.
27. Lipsky BA, Baker CA. Fluoroquinolones toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352-64.
28. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis 1999;28:299-308.
29. Burkhardt JE, Walterspiel JN, Schaad UB. Clin Infect Dis 1997;25: 1196-204 Quinolone arthropathy in animals vs children.
30. Meyboom RHB, Olsson S, Knol A, et al. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivates. Pharmacoepidemiology and Drug safety 1994;3:185-9.
31. Van Der Linden P.D., Sturkenboom M.C.J., Herings R.M.C., Leufkens H.G.M., Stricker B.H.C. A population based study of quinolones and the risk of achilles tendon rupture. Abstract 273, 40th ICAAC, September 17-20, 2000, Toronto, Canada.
32. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002 Jun;21(6):525-9.
33. Chalumeau M, Tonnelier S, d'Athis S, Tréluyer JM, Gendrel D, Bréart G, et al. Fluoroquinolone safety in pediatric patients: A prospective Multicenter cohort study in France. Pediatrics 2003;111: e714-9.
34. Parry CM, Hien TT, Dougan G, White NJ, Farrar JG. Typhoid fever. NEJM 2002;347:1770-82.